NRG Oncology study of atezolizumab and chemoradiation for patients with limited-stage small cell lung cancer completes accrual

By | July 8, 2022
The NRG Oncology/Alliance clinical trial NRG-LU005, examining the addition of the immunotherapy drug atezolizumab combined with chemoradiation for patients with limited-stage small cell lung cancer (SCLC) recently reached the trial’s accrual goal of 506 patients.